Komori
Occurring Fact130AVeritas In Silico Inc.Pharmaceuticals

Notice Regarding the Recognition of an Extraordinary Loss Due to Impairment

The Company will recognize an impairment loss of ¥135.520 million as an extraordinary loss for the tangible fixed assets acquired in the first quarter of the fiscal year ending December 2026, based on their future recoverability. Although first-quarter profit will decline, the full-year earnings forecast remains unchanged.

Worth reading
62In focus
Scored from 4 of 5 sections
Direction
Deterioration
Direction inferred from the company’s description.
Scale
135520
¥ thousand
Wording
Conditional
How definitive the wording is.

Recognition of an Extraordinary Loss Due to Impairment

Subject Entity

Veritas In Silico, Inc. (the Company)

Target Locations / Products

Tangible fixed assets acquired by the Company in the first quarter

This disclosure05/11/2026
Cause

Following a review of the future recoverability of the fixed assets held, in accordance with the Accounting Standard for Impairment of Fixed Assets

Amount of Impact on Business Performance

¥135.520 million (extraordinary loss: impairment loss)

Accounting period in which recognized

The first-quarter accounting period of the fiscal year ending December 2026

Impact on Earnings Forecast

The earnings forecast for the fiscal year ending December 2026 will remain unchanged.

Outlook

From the second quarter onward, the Company may be able to make up the shortfall through business revenue and other income expected to be generated during fiscal 2026. Although the carrying amounts of the tangible and intangible fixed assets held by the Company will decline, the impact on the assets as a whole is expected to remain limited.

Planned follow-up disclosure

The company will promptly disclose any matters that should be disclosed in the future.

Event that occurred
ItemDetails
Event nameRecognition of an Extraordinary Loss Due to Impairment
Subject EntityVeritas In Silico, Inc. (the Company)
Target Locations / ProductsTangible fixed assets acquired by the Company in the first quarter
CauseFollowing a review of the future recoverability of the fixed assets held, in accordance with the Accounting Standard for Impairment of Fixed Assets
Amount of Impact on Business Performance¥135.520 million (extraordinary loss: impairment loss)
Accounting period in which recognizedThe first-quarter accounting period of the fiscal year ending December 2026
Impact on Earnings ForecastThe earnings forecast for the fiscal year ending December 2026 will remain unchanged.
OutlookFrom the second quarter onward, the Company may be able to make up the shortfall through business revenue and other income expected to be generated during fiscal 2026. Although the carrying amounts of the tangible and intangible fixed assets held by the Company will decline, the impact on the assets as a whole is expected to remain limited.
Planned follow-up disclosureThe company will promptly disclose any matters that should be disclosed in the future.
Items this document does not state (16)
Date of occurrenceDate recognized / date notice receivedType of litigation or proceedingCourt or authorityPlaintiffDefendantDate of filing / date of actionClaim amount / surcharge amountAmount of receivables at risk of non-collection or delayed collectionSuspended operationsScheduled resumption dateInvestigation structureMeasures to prevent recurrenceDirectors' and officers' liabilityVoting rights ownership percentage before the changeVoting rights ownership percentage after the change

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

As a result of examining future recoverability in accordance with the Accounting Standard for Impairment of Fixed Assets, the Company decided to recognize an impairment loss.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Recognition of an Extraordinary Loss Due to Impairment | Veritas In Silico Inc. (130A) timely disclosure | Komori